The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019
ALBANY, New York, July 31, 2014 /PRNewswire/ --
MarketResearchreports.biz presents this most up-to-date research on Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, And Modern and Human Insulin) - Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume), 2013 - 2019: Market Size, Trends, and Forecasts Research Report.
Diabetes, growing at an exponential rate worldwide, has become a serious health concern. The disease has emerged as a major cause of death of people between 20 years and 80 years of age. According to the American Diabetes Association, around 5% of the U.S. population has type 1 diabetes (approximately 1 million) and 95% of the population suffers from type 2 diabetes. Insulin plays an integral role in absorption of glucose from blood in case of type 1 and type 2 diabetes. Eli Lilly was the first company who made the human insulin commercially available in early 1980s. Since then insulin industry has been witnessing continuous advancements and innovations with various insulin derivatives available in the market. This report on insulin market analyzes the current as well as future prospects of the global and China market for insulin. This research is designed to estimate and analyze the demand and performance of insulin in the global market and also with special focus on the insulin market in China. This report on insulin provides in-depth analysis of the insulin market by revenue, volume, price trends and trend analysis by segments and demand in the global and China market.
Browse Global and china Insulin Market Full Report with Toc: http://www.marketresearchreports.biz/analysis-details/insulin-market-global-and-china-industry-analysis-size-share-growth-and-forecast-2011-2018
The global and China insulin market is segmented based on mode of action into fast-acting insulin, short-acting insulin, long-acting insulin, intermediate-acting insulin and premixed insulin. Furthermore, the insulin market is also classified on the basis of source namely, human insulin and modern insulin. The market for these segments is extensively analyzed based on leading drug launches, expiry, efficacy, sales revenue and geographic presence. The market size, volume and forecast in terms of USD million for each type of insulin has been provided for the period 2011 to 2019, considering 2012 as the base year. This report on global and China insulin market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year.
The report concludes with profiles of major players in the insulin market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include Novo Nordisk, Sanofi, Eli Lilly and Company and Shanghai Fosun Pharmaceuticals.
The global and China insulin market is segmented as follows:
Global and China Insulin Market, by Mode of Action